Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

August 5, 2020 | Corporate News | English

Thermo Fisher Scientific to leverage Tecan’s automation technology to enable scaled-up COVID-19 testing globally

Männedorf, Switzerland, August 5, 2020 – The Tecan Group (SIX Swiss Exchange: TECN) and Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, announced today a collaboration to enable scaled-up COVID-19 testing globally. Thermo Fisher Scientific is introducing a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing. The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school.

The system includes instruments of the Tecan Fluent Laboratory Workstation family, the highest performance platform within Tecan’s extensive portfolio of liquid handling solutions for laboratory automation and the Introspect software, an instrument and consumables usage analysis and reporting software.

The Thermo Fisher Scientific Amplitude Solution is a molecular diagnostic testing system that leverages the company’s Applied Biosystems QuantStudio 7 PCR instruments along with liquid handling products from Tecan. The modular solution delivers test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources

Tecan CEO Dr. Achim von Leoprechting commented: “We are excited to partner with Thermo Fisher Scientific, supporting the efforts to further scale up COVID-19 testing capacities with our Fluent workstation and Introspect software. In this unprecedented time, we are passionately contributing to the international efforts to turn the tide on COVID-19 by empowering the scientific and clinical communities to accelerate research, aiding the discovery of treatments and scaling up testing globally.”

“Increased testing capability is an essential part of any community’s plan to reopen schools and businesses,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Current approaches to scale up testing require substantial resources and personnel. This more automated, high-throughput solution will enable laboratories around the world to increase testing volumes and help the public get their test results faster.”

The Amplitude Solution utilizes Thermo Fisher’s Applied Biosystems TaqPath COVID-19 Combo Kit, a fast, highly sensitive multiplex diagnostic test that contains the assays and controls needed for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The company will submit this new end-to-end solution to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and plans to secure additional registrations globally.

As part of this offering, Amplitude Solution customers will enter into a supply agreement with Thermo Fisher to secure an up-front, confirmed and reliable supply of reagents and consumables. Backed by dedicated, 24/7 customer support from Thermo Fisher, the end-to-end solution, including the reagents, consumables and test kits, is available from a single source.

For more information on the Amplitude Solution, please visit www.thermofisher.com/amplitude

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2019, Tecan generated sales of CHF 637 million (USD 643 million; EUR 574 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

 


 

Downloads: